びまん性大細胞型B細胞リンパ腫に対する前線化学免疫療法中のMRD適応低線量放射線療法 (MRD-XRT)
びまん性大細胞型B細胞リンパ腫における前線R-化学免疫療法とMRD適応型中期低線量放射線併用の実現可能性(MRD XRT)
This prospective Phase IIA feasibility study evaluates a minimal residual disease (MRD)-adapted treatment strategy in patients with diffuse large B-cell lymphoma (DLBCL) receiving frontline R-chemoimmunotherapy. Circulating tumor DNA (ctDNA)-based MRD testing and interim positron emission tomography (PET) imaging after two cycles of therapy are used to guide treatment decisions. Patients with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard systemic therapy. Patients with undetectable MRD, or detectable MRD without targetable residual disease, continue standard frontline chemoimmunotherapy without protocol-directed LDRT.
調査の概要
状態
状態
条件
条件
介入・治療
介入・治療
詳細な説明
Diffuse large B-cell lymphoma (DLBCL) is commonly treated with frontline R-chemoimmunotherapy regimens such as R-CHOP or related combinations. Interim positron emission tomography (PET) imaging provides information about treatment response, while circulating tumor DNA (ctDNA)-based minimal residual disease (MRD) testing allows assessment of molecular residual disease during treatment.
This prospective, non-randomized Phase IIA feasibility study evaluates the integration of ctDNA-based MRD testing and interim PET imaging into frontline treatment decisions for patients with DLBCL. Approximately 50 participants are expected to enroll.
Following two cycles of frontline R-chemoimmunotherapy, participants undergo protocol-specified MRD testing and interim PET assessment. Participants with detectable MRD and residual PET-avid or measurable disease suitable for radiation therapy are assigned to Arm A and receive protocol-directed low-dose radiation therapy (LDRT) in addition to standard frontline chemoimmunotherapy.
Participants with undetectable MRD, as well as those with detectable MRD but without targetable residual disease, are assigned to Arm B and continue standard frontline chemoimmunotherapy without protocol-directed LDRT.
The primary objective is to evaluate the feasibility of this MRD-adapted strategy, including successful completion of MRD testing after cycle 2 and delivery of protocol-directed LDRT to eligible MRD-positive participants. Secondary assessments include treatment response, progression-free survival, overall survival, the impact of LDRT on systemic treatment delivery, and patient-reported quality of life.
研究の種類
研究の種類
入学 (推定)
入学
段階
段階
- フェーズ2
連絡先と場所
研究連絡先
研究連絡先
- 名前:Krishna vamsi Gottipati, MS
- 電話番号:(402) 5593518
- メール:krgottipati@unmc.edu
研究連絡先のバックアップ
- 名前:IIT Office Clinical Trails Office
- 電話番号:(402) 5590963
- メール:IITOFFICE@unmc.edu
研究場所
-
-
Nebraska
-
Omaha、Nebraska、アメリカ、68198
- Fred & Pamela Buffet Cancer Center
-
コンタクト:
- Snegha Ananth, MBBS
- 電話番号:(402)559-3848
- メール:sananth@unmc.edu
-
-
参加基準
適格基準
適格基準
就学可能な年齢
健康ボランティアの受け入れ
受講資格のある性別
説明
Inclusion Criteria:
- Adults ≥19 years of age
- Biopsy-proven newly diagnosed DLBCL, transformed from indolent lymphoma, Follicular lymphoma grade 3B, post-transplant lymphoproliferative disorder, or any other subtypes of Large B-cell lymphoma under WHO-HAEM5 classification who are eligible and plan to receive 6 cycles of R-chemoimmunotherapy. Note: patients may receive up to one cycle of R-chemoimmunotherapy prior to enrollment.
- Planned to receive 6 cycles of frontline R-chemoimmunotherapy for diseases mentioned in criterion 2
- Presence of measurable disease on imaging, nodal lesion >1.5cm or extra-nodal lesion >1 cm prior to initiation of R-chemoimmunotherapy
- Availability of sufficient and viable baseline FFPE tumor tissue to allow development of a personalized MRD assay
Exclusion Criteria:
- Limited stage (Ann Arbor stage I-II) DLBCL, requiring less than 6 cycles of R-chemoimmunotherapy
- Primary or secondary CNS lymphoma
- Subject has exceeded maximum lifelong cumulative doses of radiation therapy or is unsafe for radiation therapy as determined by the investigator and/or radiation oncologist
- Pregnant and lactating patients
- Has received two or more cycles of R-chemoimmunotherapy relating to this disease
研究計画
研究はどのように設計されていますか?
デザインの詳細
- 主な目的:処理
- 割り当て:非ランダム化
- 介入モデル:並列代入
- マスキング:なし(オープンラベル)
アーム数
武器と介入
参加者グループ / アーム参加者グループ / アーム |
介入・治療介入・治療 |
|---|---|
|
実験的:Arm- A: MRD-Detectable with Protocol-Directed LDRT
Participants with detectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy and residual PET-avid or measurable disease suitable for radiation therapy receive protocol-directed low-dose radiation therapy (LDRT) to targetable residual disease sites in addition to standard frontline chemoimmunotherapy. |
Low-dose radiation therapy delivered to residual PET-avid disease sites identified after interim assessment with PET imaging and MRD testing. Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician. |
|
アクティブコンパレータ:Arm B: Standard Therapy Without Protocol-Directed LDRT
Participants with undetectable circulating tumor DNA minimal residual disease (ctDNA MRD) after cycle 2 of frontline R-chemoimmunotherapy, or participants with detectable MRD but without residual PET-avid or measurable disease suitable for radiation therapy, continue standard frontline chemoimmunotherapy without protocol-directed low-dose radiation therapy (LDRT). |
Standard-of-care frontline chemoimmunotherapy regimens for diffuse large B-cell lymphoma, including R-CHOP, Pola-R-CHP, DA-EPOCH-R, R-CEOP, or related regimens as determined by the treating physician. |
この研究は何を測定していますか?
主要な結果の測定
主要な結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Feasibility of Real-Time MRD-Guided Treatment Strategy
時間枠:From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).
|
Feasibility will be assessed by the proportion of enrolled patients who successfully complete protocol-specified MRD testing after two cycles of chemoimmunotherapy and, among patients with detectable MRD, the proportion who successfully receive protocol-defined low-dose radiation therapy (LDRT). Feasibility will be considered acceptable if at least 80% of enrolled patients complete MRD testing and at least 80% of ctDNA-positive patients receive LDRT. |
From interim MRD assessment after Cycle 2 through completion of protocol-directed low-dose radiation therapy (LDRT) before Cycle 5 Day 1 (approximately 12 weeks after treatment initiation).
|
二次結果の測定
二次結果の測定
結果測定 |
メジャーの説明 |
時間枠 |
|---|---|---|
|
Overall response rate (ORR), Including Complete Response (CR) and Partial Response (PR) Rates
時間枠:At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
The proportion of participants achieving complete response (CR) or partial response (PR), with complete response rate assessed separately. Response will be evaluated using PET/CT imaging according to Lugano 2014 criteria. |
At end-of-treatment response assessment following completion of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
|
Progression-Free Survival (PFS)
時間枠:From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
Progression-free survival is defined as the time from initiation of frontline therapy until disease progression or death from any cause. PFS will be estimated using the Kaplan-Meier method. |
From initiation of frontline therapy until disease progression or death, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
|
Overall Survival (OS)
時間枠:From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
Overall survival is defined as the time from initiation of frontline therapy until death from any cause. OS will be estimated using the Kaplan-Meier method. |
From initiation of frontline therapy until death from any cause, with follow-up for approximately 2 years after completion or discontinuation of treatment.
|
|
Impact of Low-Dose Radiation Therapy on Delivery of Systemic Chemoimmunotherapy
時間枠:From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
The impact of protocol-directed low-dose radiation therapy (LDRT) on the delivery of planned systemic chemoimmunotherapy will be assessed by treatment delays, dose reductions, omitted chemotherapy cycles, or premature discontinuation of systemic therapy attributable to LDRT. |
From initiation of protocol-directed LDRT through completion or discontinuation of frontline chemoimmunotherapy (approximately 6 months after treatment initiation).
|
|
European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30)
時間枠:At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).
|
Patient-reported quality of life will be assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire-Core 30 (EORTC QLQ-C30), evaluating global health status, functional domains, and symptoms. |
At the end of treatment (end of Cycle 6 of frontline chemoimmunotherapy, approximately 6 months after treatment initiation).
|
協力者と研究者
捜査官
捜査官
- 主任研究者:Snegha Ananth, MBBS、University of Nebraska
研究記録日
主要日程の研究
研究開始 (推定)
研究開始
一次修了 (推定)
一次修了
研究の完了 (推定)
研究の完了
試験登録日
最初に提出
最初に提出
QC基準を満たした最初の提出物
QC基準を満たした最初の提出物
最初の投稿 (実際)
最初の投稿
学習記録の更新
投稿された最後の更新 (実際)
投稿された最後の更新
QC基準を満たした最後の更新が送信されました
QC基準を満たした最後の更新が送信されました
最終確認日
最終確認日
詳しくは
本研究に関する用語
追加の関連 MeSH 用語
その他の研究ID番号
その他の研究ID番号
- 0342-26-FB
医薬品およびデバイス情報、研究文書
米国FDA規制医薬品の研究
米国FDA規制機器製品の研究
この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。